Tag: sevabertinib
-
Bayer’s Hyrnuo Wins First-Line FDA Approval in HER2-Mutant Lung Cancer
The FDA granted Bayer’s Hyrnuo accelerated approval as a first-line treatment for HER2-mutant non-small cell lung cancer after the oral therapy achieved a 75% response rate in SOHO-01.
-
How Hyrnuo Blocks Mutant HER2 Signaling in Lung Cancer
Activating HER2 mutations can sustain RAS–ERK and PI3K–AKT signaling in lung cancer. This explainer examines how Hyrnuo reversibly inhibits mutant HER2 kinase activity while limiting wild-type EGFR inhibition.